Nanoparticles and nanoparticle formulations or suspensions are provided which comprise a fibrate and vitamin E TPGS. The nanoparticles may have a mean diameter measured by photon correlation spectroscopy in the range of from about 100 nm to about 900 nm. Pharmaceutical formulations and uses of such compositions are also provided.

The invention concerns a pharmaceutical composition containing micronized fenofibrate a surfactant and a binding cellulose derivative as solubilizing adjuvant preferably hydroxypropylmethylcellulose. The cellulose derivative represents less than 20 wt. % of the composition. The association of micronized fenofibrate with a binding cellulose derivative as solubilizing adjuvant and a surfactant enables to enhance the bioavailability of the active principle. The invention also concerns a method for ...

Various fenofibrate dosage forms contain a plurality of beads or particles, where the beads or particles include a pharmaceutical composition comprising fenofibrate

Various fenofibrate compositions include a plurality of first granules having a high bioavailability in vivo, and a plurality of second granules having a low bioavailability in vivo. The first granules may comprise fenofibrate, from 0.3% to 10% by weight of the first granules of a first surfactant, and a first water soluble or water dispersible cellulose derivative, and the second granules may comprise fenofibrate, from 0% to 0.25% by weight of the second granules of a second surfactant, and a s...

Various fenofibrate compositions include a plurality of first granules having a high bioavailability in vivo and a plurality of second granules having a low bioavailability in vivo. The first granules may comprise fenofibrate from 0.3% to 10% by weight of the first granules of a first surfactant and a first water soluble or water dispersible cellulose derivative and the second granules may comprise fenofibrate from 0% to 0.25% by weight of the second granules of a second surfactant and a second ...

Various fenofibrate compositions include a plurality of first granules having a high bioavailability in vivo, and a plurality of second granules having a low bioavailability in vivo. The first granules may comprise fenofibrate, from 0.3% to 10% by weight of the first granules of a first surfactant, and a first water soluble or water dispersible cellulose derivative, and the second granules may comprise fenofibrate, from 0% to 0.25% by weight of the second granules of a second surfactant, and a s...

593784 Disclosed is the use of a fibrate selected from fenofibrate, fenofibric acid, and a salt of fenobiric acid, for the preparation of a medicament useful for the treatment of sleep apnea or sleep apnea syndrome. In particular the condition is obstructive sleep apnea or obstructive sleep apnea syndrome. Example of fribrate is fenofibrate also known as propan-2-yl 2-{ 4-[(4-chlorophenyl)carbonyl]phenoxy} -2-methylpropanoate.